pneumococcal 20-valent conjugate vaccine
pneumococcal 20-valent conjugate vaccine: 3 clinical trials tracked.
pneumococcal 20-valent conjugate vaccine evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about pneumococcal 20-valent conjugate vaccine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence0 indications · 1 study sponsors
Related indications
No linked indication is available.
Study sponsors
Clinical Trial Registry Records (3)
A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Prior Pneumococcal Vaccination
Primary endpoint: Serotype-specific OPA geometric mean titers (GMT)
A Phase 1, Randomized, Double-Blind, Active Comparator Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Novel Pneumococcal Vaccine in Children
Primary endpoint: Stage 1: Percentage of Participants With Immediate Adverse Events (AEs) Following Vaccination
A Phase 3, Randomized, Double-Blind, Active-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Subjects 50 Years of Age and Older With Immunobridging to Subjects 18-49 Years of Age
Primary endpoint: Serotype-specific OPA geometric mean titers (GMT) in 50 year olds and above